Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study
Wiadomości Lekarskie · 30.04.2026 · (4) · 736-744
DOI: 10.36740/wlek/216191 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Wiadomości Lekarskie, online erschienen am 30.04.2026. Verfasst von Laith Rhabneh und 3 weiteren Autor:innen. Beteiligte Einrichtung: DEPARTMENT OF INTERNAL MEDICINE, HACKENSACK MERIDIAN HEALTH OCEAN UNIVERSITY MEDICAL CENTER, BRICK TOWNSHIP, UNITED STATES. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Cognitive Dysfunction, Heart Failure.
Abstract (Originalsprache)
Aim
The purpose of this study was to compare 5-year cognitive outcomes in patients with HFrEF who receive angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Material and methods Retrospective cohort study of: 1) 135,873 adults with HFrEF (International Classification of Diseases-10th Revision-Clinical Modification [ICD-10-CM] codes: I50.2 or I50.4) started on ACEI between Aug 1, 2019 and Aug 1, 2024; and 2) 135,873 propensity matched patients receiving ARBs during that time. Data were obtained from the TriNetX Research Network, encompassing 80 health care organizations in the United States. The primary endpoint was the composite of cognitive decline (ICD-10-CM: R41.8), dementia (ICD-10-CM: F01-F03), and Alzheimer’s disease (ICD-10- CM: G30).
Results
At 5 years,17,679 patients on ACEI met the primary endpoint vs 16,345 patients on ARBs (5-year incidence: 30.71% vs 28.54%; HR: 1.153; 95% CI: 129-1.178; P < 0.001), with consistently higher rates of cognitive decline (24.94% vs 22.81%; HR: 1.146; 95% CI: 1.119-1.174; P < 0.001), dementia (15.63% vs 13.71%; HR:1.204; 95% CI: 1.168-1.241; P < 0.001), and Alzheimer’s disease (4.15% vs 3.51%; HR: 1.202; 95% CI: 1.131-1.277; P < 0.001) in the ACEI cohort.
Conclusions
ACEI was associated with higher 5-year rates of neurocognitive disorders when compared to ARBs in patients with HFrEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DEPARTMENT OF INTERNAL MEDICINE, HACKENSACK MERIDIAN HEALTH OCEAN UNIVERSITY MEDICAL CENTER, BRICK TOWNSHIP, UNITED STATES.
- DEPARTMENT OF INTERNAL MEDICINE, ASCENSION SAINT AGNES HOSPITAL, BRICK TOWNSHIP, UNITED STATES.
- INTERNAL MEDICINE DEPARTMENT, UNIVERSITY OF MARYLAND MIDTOWN CAMPUS, BALTIMORE, UNITED STATES.
Zitieren
APA
Rhabneh, L., Ababneh, R., Al-Muhtaseb, A., & Aloqaily, M. (2026). Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study. Wiadomości Lekarskie, 736-744. https://doi.org/10.36740/wlek/216191
Vancouver
Rhabneh L, Ababneh R, Al-Muhtaseb A, Aloqaily M. Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study. Wiadomości Lekarskie. 2026:736-744. doi:10.36740/wlek/216191
BibTeX
@article{Rhabneh2026,
author = {Rhabneh, Laith and Ababneh, Raed and Al-Muhtaseb, Abdallah and Aloqaily, Mohammed},
title = {Effects of Angiotensin Converting Enzyme Inhibitors versus Angiotensin Receptor Blockers on Cognitive Decline: A Retrospective Real-World Database Study},
journal = {Wiadomości Lekarskie},
year = {2026},
number = {4},
pages = {736--744},
doi = {10.36740/wlek/216191}
}
EUVIMED